Nelson Van Denburg & Campbell Wealth Management Group LLC Boosts Stake in Sarepta Therapeutics Inc (NASDAQ:SRPT)

Share on StockTwits

Nelson Van Denburg & Campbell Wealth Management Group LLC increased its stake in shares of Sarepta Therapeutics Inc (NASDAQ:SRPT) by 17.6% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 3,280 shares of the biotechnology company’s stock after purchasing an additional 490 shares during the period. Nelson Van Denburg & Campbell Wealth Management Group LLC’s holdings in Sarepta Therapeutics were worth $247,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of SRPT. Evolution Wealth Advisors LLC purchased a new position in Sarepta Therapeutics in the 2nd quarter valued at approximately $25,000. Trust Co. of Vermont boosted its position in Sarepta Therapeutics by 2,125.0% in the 2nd quarter. Trust Co. of Vermont now owns 178 shares of the biotechnology company’s stock valued at $27,000 after buying an additional 170 shares during the period. Steward Partners Investment Advisory LLC purchased a new position in Sarepta Therapeutics in the 2nd quarter valued at approximately $32,000. BSW Wealth Partners purchased a new position in Sarepta Therapeutics in the 2nd quarter valued at approximately $52,000. Finally, Coastal Investment Advisors Inc. boosted its position in Sarepta Therapeutics by 57.4% in the 2nd quarter. Coastal Investment Advisors Inc. now owns 425 shares of the biotechnology company’s stock valued at $64,000 after buying an additional 155 shares during the period. 95.09% of the stock is owned by hedge funds and other institutional investors.

In related news, Director M Kathleen Behrens purchased 2,500 shares of the business’s stock in a transaction that occurred on Friday, September 6th. The shares were purchased at an average cost of $87.98 per share, for a total transaction of $219,950.00. Following the purchase, the director now directly owns 123,167 shares of the company’s stock, valued at $10,836,232.66. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Douglas S. Ingram purchased 16,252 shares of the business’s stock in a transaction that occurred on Monday, August 12th. The shares were bought at an average price of $123.07 per share, for a total transaction of $2,000,133.64. Following the completion of the purchase, the chief executive officer now directly owns 424,405 shares in the company, valued at $52,231,523.35. The disclosure for this purchase can be found here. Over the last ninety days, insiders have bought 35,752 shares of company stock valued at $3,940,114. Corporate insiders own 6.60% of the company’s stock.

Sarepta Therapeutics stock opened at $83.16 on Friday. The stock has a market cap of $5.99 billion, a P/E ratio of -15.23 and a beta of 2.12. The company has a fifty day simple moving average of $85.44 and a 200-day simple moving average of $118.16. Sarepta Therapeutics Inc has a 12-month low of $72.05 and a 12-month high of $158.80. The company has a current ratio of 8.81, a quick ratio of 7.84 and a debt-to-equity ratio of 0.44.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported ($3.74) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.08) by ($2.66). The firm had revenue of $94.67 million for the quarter, compared to analysts’ expectations of $91.05 million. Sarepta Therapeutics had a negative return on equity of 55.37% and a negative net margin of 165.52%. Sarepta Therapeutics’s revenue for the quarter was up 28.8% on a year-over-year basis. During the same period last year, the firm posted ($1.67) earnings per share. As a group, sell-side analysts forecast that Sarepta Therapeutics Inc will post -4.94 earnings per share for the current fiscal year.

Several equities analysts have commented on the stock. Janney Montgomery Scott decreased their price target on shares of Sarepta Therapeutics from $200.00 to $175.00 and set a “buy” rating for the company in a research report on Tuesday, August 20th. Robert W. Baird decreased their price target on shares of Sarepta Therapeutics from $202.00 to $181.00 and set an “outperform” rating for the company in a research report on Tuesday, August 20th. Credit Suisse Group decreased their price target on shares of Sarepta Therapeutics from $207.00 to $201.00 and set an “outperform” rating for the company in a research report on Tuesday, August 20th. Evercore ISI reissued a “buy” rating and issued a $200.00 price target on shares of Sarepta Therapeutics in a research report on Thursday, August 8th. Finally, Cantor Fitzgerald decreased their price target on shares of Sarepta Therapeutics from $231.00 to $175.00 and set an “overweight” rating for the company in a research report on Tuesday, August 20th. One equities research analyst has rated the stock with a sell rating, twenty-one have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $191.28.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare diseases. The company offers EXONDYS 51, a disease-modifying therapy for duchenne muscular dystrophy (DMD). Its products pipeline include Golodirsen, a product candidate that binds to exon 53 of dystrophin pre-mRNA, which results in exclusion or skipping of exon during mRNA processing in patients with genetic mutations; and Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene.

See Also: Technical Indicators – What is a Golden Cross?

Institutional Ownership by Quarter for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Concho Resources Inc Forecasted to Earn FY2019 Earnings of $2.76 Per Share
Concho Resources Inc Forecasted to Earn FY2019 Earnings of $2.76 Per Share
Jefferies Financial Group Weighs in on PADDY PWR BETFA/ADR’s FY2019 Earnings
Jefferies Financial Group Weighs in on PADDY PWR BETFA/ADR’s FY2019 Earnings
FY2019 Earnings Forecast for Masco Corp Issued By SunTrust Banks
FY2019 Earnings Forecast for Masco Corp Issued By SunTrust Banks
Cormark Brokers Decrease Earnings Estimates for CES Energy Solutions Corp
Cormark Brokers Decrease Earnings Estimates for CES Energy Solutions Corp
FY2019 EPS Estimates for H&R Real Estate Investment Trust  Lowered by National Bank Financial
FY2019 EPS Estimates for H&R Real Estate Investment Trust Lowered by National Bank Financial
Barclays Reaffirms “Overweight” Rating for AstraZeneca
Barclays Reaffirms “Overweight” Rating for AstraZeneca


© 2006-2019 Ticker Report